Milestone Scientific Inc ((MLSS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Scientific’s latest earnings call painted a cautiously optimistic picture, with management emphasizing tangible operational progress against a still‑fragile financial backdrop. Restructuring and cost cuts have sharply narrowed operating losses and supported modest revenue growth, yet liquidity remains tight and the path to profitability hinges on successful execution of new commercial and reimbursement strategies.
Revenue Growth and Scale Remain Modest
Milestone reported Q4 2025 revenue of $2.1 million, up 2.2% or $45,000 from the prior year, while full‑year net sales rose 4% to $9.0 million from $8.6 million. The uptick confirms demand is edging higher, but the low‑single‑digit growth rate underscores that the company is still in the early stages of scaling its dental and CompuFlo businesses.
Sharp Improvement in Quarterly Operating Loss
The standout metric was the dramatic improvement in Q4 operating loss, which narrowed to $1.1 million, an 89% improvement versus the $2.0 million loss a year earlier. This shift points to a leaner cost structure and suggests that incremental revenue may now translate more efficiently to the bottom line if growth accelerates.
Cost Actions Cut Full-Year Losses
For 2025, the operating loss improved to $5.7 million from $6.8 million, a $1.1 million reduction driven mainly by lower SG&A, dental‑related expenses and R&D after restructuring. Management framed these cuts as targeted rather than across‑the‑board, aiming to preserve growth initiatives while stabilizing the company’s cash burn.
Guidance Calls for Higher Growth and Leverage
Looking ahead, Milestone guided 2026 revenue to a range of $9.8 million to $10.2 million, implying double‑digit growth from 2025 levels. The company expects CompuFlo alone to contribute $500,000 to $600,000 in 2026, around a 400% jump versus 2025, and believes this mix shift plus prior cost cuts will drive better operating leverage and materially reduce cash usage.
New Commercial Push in Dental via Ambassadors
Post‑restructuring, Milestone has pivoted to targeted digital marketing and commercial investments, highlighted by the Wand Ambassador program. Launched as a pilot in December and rolled out nationally in January 2026, the program has recruited roughly 175 ambassadors and generated about 30 product demos so far, with management projecting a few hundred thousand dollars in incremental dental sales for 2026.
CompuFlo Reboot and Reimbursement Build-Out
CompuFlo commercialization was relaunched with a structured Advisor program, enlisting more than 10 physician partners to advocate for the technology in pain management settings. To support adoption, Milestone has brought in two seasoned Medicare specialists and set up a three‑ to four‑person call center to help providers navigate reimbursement, while also pursuing broader Medicare, VA and new distribution channels.
Gross Margins Holding Near 70% Target
Management reiterated expectations for gross margins to remain roughly in the 70% range, providing an attractive foundation if volumes rise. Q4 gross profit held steady at $1.5 million year over year, and full‑year gross profit was flat at $6.4 million, indicating solid unit economics even as the revenue base remains relatively small.
Liquidity Tight with Limited Balance Sheet Flexibility
Despite operational gains, Milestone’s balance sheet remains constrained, with only $1.1 million in cash and $800,000 of debt as of December 31, 2025. This thin liquidity cushion heightens near‑term risk and may force the company to seek additional capital if growth or reimbursement milestones are delayed.
Persistent Net Losses and Delayed Breakeven
The company still posted a substantial full‑year net loss of $5.7 million, or $0.07 per share, underscoring that it is far from profitability. Management’s roadmap targets cash‑flow breakeven only by early 2027, leaving several years in which execution must be strong and funding sufficient to bridge the gap.
Flat Gross Profit Highlights Scale Challenge
Both Q4 and full‑year gross profit were flat despite higher revenue, reflecting product mix and cost structure changes that muted the benefit of top‑line growth. For investors, this underscores that meaningful earnings improvement will require not just higher sales, but also consistent margin management and a faster ramp in higher‑value offerings like CompuFlo.
Regulatory and International Expansion Risks
Milestone is advancing registrations in Japan, India and Mexico, with management indicating these efforts are about 85% to 90% complete. However, the company’s 2026 guidance deliberately excludes any revenue from these markets, acknowledging that regulatory timing is uncertain and that international upside remains a potential, not a near‑term driver.
Execution Risk in CompuFlo Adoption and Reimbursement
The bullish CompuFlo outlook assumes a significant ramp, yet reimbursement is currently active in only a limited cluster of Medicare administrative regions. Broader Medicare and VA adoption, along with hospital and clinic uptake, must materialize for the projected 400% revenue increase to hold, leaving investors exposed to execution and policy‑driven delays.
Unproven Conversion from Early Commercial Programs
While the Wand Ambassador program’s roughly 175 ambassadors and 30 demos show early engagement, conversion into recurring, material revenue is not yet evident. Management believes the initiative can move the needle for dental sales, but investors will be watching 2026 metrics closely to see whether these pilots scale or stall.
Operational and External Headwinds
Management also flagged external pressures such as tariffs, which could weigh on margins if trade costs rise. The call additionally featured an apparent inconsistency in year‑over‑year net loss comparisons, which may prompt some investors to scrutinize financial reporting clarity more closely as the company navigates its turnaround.
Forward-Looking Guidance and Strategic Priorities
The 2026 outlook centers on lifting revenue to $9.8 million to $10.2 million, sustaining gross margins near 70% and harnessing past cost actions to shrink cash burn. Key levers include under‑2% penetration of the U.S. dental market, scaling the Wand Ambassador and CompuFlo Advisor programs, expanding reimbursement across more regions and government channels, and progressing international registrations that could drive longer‑term upside.
Milestone’s earnings call outlined a credible path toward higher growth and better efficiency, but also underscored how much still has to go right. With limited cash, continued losses and reliance on new commercial and reimbursement wins, the story remains high‑risk, high‑reward, and investors will need to monitor 2026 execution closely to gauge whether the turnaround is firmly taking hold.